Supplement Firms Cannot “Contract Out” GMP Responsibility – FDA
This article was originally published in The Tan Sheet
The agency’s Florida district office, in three recent warning letters, says although a firm may contract out certain supplement manufacturing operations, “it cannot, by the same token, contract out its ultimate responsibility to ensure that” its products are not adulterated.
You may also be interested in...
Misbranding due to incorrect dosing information on labels also noted in warning letters FDA posts on Jan. 19 to Alkebulan International, Nutraloid Labs, Nutrafill and Perfect Water and Essentials.
ForMor contests a warning letter from FDA stating that as an own-label distributor, the firm is subject to both packager and labeler GMP requirements. The firm says it is only a “holder” of finished products and FDA bases its warning on the GMP rule preamble, not the actual rule.
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.